It is mainly used to treat non-small cell lung cancer (NSCLC) caused by EGFR gene mutations, such as exon 19 deletions, exon 21 L858R substitutions, and T790M resistance mutations (Cross et al., 2014; Hochmair et al., 2019; Bertoli et al., 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.